Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$-55 Mln
ROE
-1.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.2
Industry P/E
--
EV/EBITDA
0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
4,902,260
CFO
$-214.35 Mln
EBITDA
$-218.41 Mln
Net Profit
$-241.64 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
| -98.2 | -47.2 | -94.4 | -98.9 | -86.3 | -80.1 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
| -10.8 | -65.3 | -28.3 | -79.4 | -33.3 | -65.8 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
0.3 | 2.7 | 0.7 | -55.2 | -8,350.1 | -211.2 | -- | 0.2 |
| 21.1 | 1,088.5 | 0.5 | -147.4 | -29,734.7 | -150.3 | -- | 6.4 | |
| 29.4 | 1,904.4 | 1,112.2 | 320.9 | -17.8 | 10.5 | 5.2 | 0.5 | |
| 15.4 | 2,582.6 | 550.0 | 458.1 | -3.3 | 45.9 | 5.4 | 1.9 | |
| 5.5 | 557.3 | 9.2 | -184.2 | -518.6 | 265.7 | -- | 2.1 | |
| 14.8 | 1,937.0 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.2 | |
| 16.6 | 1,115.4 | 321.1 | 2.4 | 1,727.2 | 1.1 | 400.3 | 3.9 | |
| 3.3 | 568.7 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.3 | |
| 15.5 | 350.6 | 4.8 | 53.5 | -- | 12.2 | 8.5 | 1.0 | |
| 20.4 | 2,015.9 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 2.8 |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta... (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. On June 1, 2022, Zosano Pharma Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. Read more
Sr. VP of Operations, Pres, CEO & Director
Mr. Steven Lo
Sr. VP of Operations, Pres, CEO & Director
Mr. Steven Lo
Headquarters
Fremont, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Zosano Pharma Corporation (ZSAN) is $0.30 (NASDAQ) as of 08-Jul-2022 09:30 EDT. Zosano Pharma Corporation (ZSAN) has given a return of -86.28% in the last 3 years.
Since, TTM earnings of Zosano Pharma Corporation (ZSAN) is negative, P/E ratio is not available.
The P/B ratio of Zosano Pharma Corporation (ZSAN) is 0.16 times as on 08-Jul-2022, a 96 discount to its peers’ median range of 4.12 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Zosano Pharma Corporation (ZSAN) are Rs -- and Rs -- as of 04-Apr-2026.
Zosano Pharma Corporation (ZSAN) has a market capitalisation of $ 3 Mln as on 08-Jul-2022. As per SEBI classification, it is a company.
Before investing in Zosano Pharma Corporation (ZSAN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.03
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.